Vyleesi actually gets a mention!

endymion96

2nd Longest Active Member
I'm not sure what the hell Palatin is doing with Vyleesi? Seems the AMAG deal and eventual debacle has killed all momentum for this drug. I don't know if Palatin can turn it around before the patents expire. The Vyleesi play was supposed to fund the rest of the pipeline, but now all hope hinges on the DED phase 3 trial and approval. I invested big time into this company and I'm worried that it isn't going to happen? Not sure if I should cut bait on this or not. What are your thoughts?
 

macgyver

Well-known member
I would not be surprised if Clinuvel is monitoring the situation closely regards bremelanotide. Given its potency and BBB permeability, and Clinuvel stating their wish to be a specialty pharmaceutical entity (melanocortins), I can see a tie up or licensing deal somewhere down the track. Palatin's management would have to have rocks in their head if they denied a proposition from Clinuvel given its pipeline and formulations.
 

endymion96

2nd Longest Active Member
@macgyver Clinuvel could certainly assist with manufacturing and distribution in the future if they acquired ... or loaned money for shares in the company (i.e. to eventually take it over like Relief did with the ACER deal).
 

sharelooker

Well-known member
The company is at the cusp of death! Now traded at 36 cents with a mcap of $83m.

They tried to refresh the company by designing a new logo and website but it didn't work. Further stock dilution is not possible at this price level. So the only chance to survive the next 6 months is to make a deal = selling vylesi or the rights for it to another company.

I think, PW is very much interested in this molecule since he has already filed a patent with breme and its application.
 

endymion96

2nd Longest Active Member
Latest 8-K came out Nov 15. They have enough cash to get them through 2022, about $60mln. Readout of ph3 for DED expected H1-2022, plus a couple ph2 trials on-going, and hopefully re-license of Vyleesi to a "committed" woman's healthcare company. All hope lies on this and a great readout for DED. Like Scenesse, I have no doubt about the efficacy of their drug. I am a believer in the synthetic peptide, not the company's ability to execute. Eventually, I will see results ... but Clinuvel would be in a position to purchase and really take over the melanocortin market with both a linear and a cyclic version of the a-MSH hormone.

 

Texas T

Well-known member
I said to myself that if the share price ever dropped to the US$ 30-cent range, I would double down and buy more shares. I have so many shares already at an average cost of about 70 cents, and was hoping by this time to be a seller for a profit, but now that the share price is around 35 cents, perhaps it is a bargain and worth buying more. I am reminded of late 2013 when Clinuvel dropped below 1$US. If the drugs in the PTN pipeline are just as amazing, or mostly so, as Afamelanotide, then perhaps PTN can follow the same path.
 

endymion96

2nd Longest Active Member
@Texas T Yeah its a tough decision when the chips are down. I have 50k shares at about 0.90 cents average. I did not expect the Vyleesi debacle to happen. That totally changed my investment hopes. Like you, I was expecting I'd be cashing in some chips by now. I'm stuck in this company like I am in Clinuvel, but the prospects seem better for CUV. I decided that diversity is the key to investing so, while the price is tempting at these levels, I've got other irons in the fire. Hoping one of my investments actually gets me to the promised land soon. I guess I can wait another 2-3 years but JESUS take the wheel!
 

Texas T

Well-known member
Damn!! As soon as I decided to buy more shares, the PTN share price jumps from 35 cents to 81 cents before I can even buy a share. However, since the share price is now above my average cost, I think I will become a seller of shares pretty soon. I can easily see the share price dropping back to 50 cents once the hype over the potential COVID treatment cools off.
 

endymion96

2nd Longest Active Member
@Texas T I could see the sentiment for selling on this step up; however, after years of investment in this company, I believe ph3 for DED is the winning ticket. Also Vyleesi sales are picking up. That is still a big market to be exploited. I believe 2022 will be the pivital year for Palatin so I am going down with the ship, lol. I'm not selling a share. Like Clinuvel, I have the most faith in the synthetic peptide, not management. My belief is rock-solid. If I hold on long enough, it will pay off in the end.

I was reading over in Uhohinc's google groups page and he seems to think there are a multitude of indications in the optical area. The eye has many cells which present MCR1 so it makes sense that a drug that can bind to that receptor would have a significant beneifical effect. And given the delivery method is eye drops, it cannot get any simplier or easier than that. Maybe I should have bought more shares at 0.35 cents? Always second guessing myself?
 

endymion96

2nd Longest Active Member
@Texas T yeah, that's fine. It just tells me that these millenials don't even know what they are investing in. They have been rasied to expect immediate satisfaction. If an investment doesn't do well in 6 months, they give up and go to the next shiny thing. Most of the sell off, IMO, was due to people who have only been invested for a year or two and wanted to get out. That is short-sighted. I read the message boards frequently so I have a feel for your typical "investor". They aren't investing, they are gambling.
 

CUV Quote (Yesterday's close)

Time: 11:03AM AEDT
Price: 22.16
Volume: 50578
Top